Four-ring medicine antihypertensive drug approved clinical trial

Client to view the latest market install Sina Financial Client: anytime, anywhere mobile phone to see Hong Kong stocks unlimited free stock price reminder
Sina Financial News September 10 news, according to Caihua News, Four Rings Pharmaceutical Holdings (00460-HK) announced that the group's innovative drug research and development team independently developed 1.1 types of patented innovative drug Tere teal acid tyebic (or the new drug), the National Drug Administration of China issued a of clinical trials in china, the united states, new batch It is the group's sixth class of patented new drugs to receive clinical approval.　　The bulletin mentions that teraetin hydrochloric acid is an antihypertensive drug in the l/T-type calcium ion double-channel inhibitor class Calcium ion antagonists are the most widely used antihypertensive drugs in the Asian population, and the drugs currently on the market mainly control blood pressure by inhibiting L-type calcium ion channels and can relieve stroke; Teretei hydrochloric acid is a L/T-type calcium ion double-channel inhibitor, preclinical studies show that not only has excellent blood pressure reduction effect, the heart and kidneys also have a protective effect, and can significantly reduce L-type calcium ion antagonists class blood pressure-lowering drugs caused by peripheral edema, safety is better than the current market of similar drugs.　　If teal itist is successfully marketed, it will be a more competitive antihypertensive innovation, providing clinicians and patients with high blood pressure with better treatment options (Natural) Enter sina financial stock bar discussion